Home » Trials » SLCTR/2024/031


A double blinded randomized control trial – the impact of religious chanting on post operative pain and recovery following laparoscopic cholecystectomy.

-

SLCTR Registration Number

SLCTR/2024/031


Date of Registration

25 Sep 2024

The date of last modification

Nov 11, 2024



Application Summary


Scientific Title of Trial

A double blinded randomized control trial – the impact of religious chanting on post operative pain and recovery following laparoscopic cholecystectomy.


Public Title of Trial

A double blinded randomized control trial – the impact of intraoperative religious chanting vs standard care on post operative pain and recovery following laparoscopic cholecystectomy.


Disease or Health Condition(s) Studied

Post Cholecystectomy pain


Scientific Acronym

None


Public Acronym

None


Brief title

None


Universal Trial Number

U1111-1313-7086


Any other number(s) assigned to the trial and issuing authority

Ethics Committee Ref: P/71/06/2024


Trial Details


What is the research question being addressed?

Is religious chanting effective in reducing post operative pain and hastening recovery following laparoscopic cholecystectomy compared to standard treatment?


Type of study

Interventional


Study design

Allocation

Randomized controlled trial


Masking

Double blinded : Participants, Investigators, Data analysts, Healthcare providers, Outcome assessors


Control

Standard therapy/practice


Assignment

Parallel


Purpose

Other


Study Phase

Not Applicable


Intervention(s) planned

Study Setting - Surgical professorial unit in North Colombo Teaching hospital, Ragama. Consecutive, consenting patients who meet inclusion criteria will be sampled. Patient assessment will comprise of a detailed medical history obtained by a medical officer. This will encompass the detection of any co-morbidities and any contraindications for anesthesia. This will also include details of the patient’s religion and his preference of religious chants. All patients will be reviewed by the anesthetic team. Optimization of the essential drugs will be ensured and the patient will be admitted to the ward one day prior to the surgery to undertake preparatory measures.

Pre-operatively the patient will be counselled regarding the trial and informed written consent obtained. Patients will be allocated to two groups using random number tables. The randomization of the patients will be done in the theatre prior to surgery. Patients will be randomized into intervention and control groups by a designated medical officer and the application of headphones will be done by the same medical officer who will not be blinded. He will not take part in the post operative or intra operative care of the patient. The attending anesthetist remains blinded throughout the surgery. The Surgeon who will take decisions with regards to patient management and discharge will not be aware of the patient groups.

Treatment Plan : During laparoscopic cholecystectomy patient is kept supine. General anesthesia and orogastric intubation are offered routinely. All patients will receive 100?g of iv fentanyl, 1-2mg/kg of propofol, 0.6mg/kg of atracurium for intubation and 0.1mg/kg morphine at the induction. Intra venous cefuroxime 1.5mg will be given prophylactically with the induction provided there are no allergies. Patients head end is elevated 10-20 degrees and the table tilted to the left side. Umbilicus is infiltrated with 3-5ml of 0.5% Bupivacaine in all cases. A 10 mm umbilical port is inserted using the open technique. 12mmHg pneumoperitoneum is created.
Muscle relaxation was maintained with IV atracurium and anesthesia maintained with Isoflurane in a 50%:50% combination of oxygen mixed with air. Isoflurane concentration was adjusted to attain a Minimum Alveolar Concentration (MAC) of 1.0 throughout surgery. In the theater standard anesthetic monitoring will be carried out with continuous electrocardiography (ECG), non-invasive blood pressure monitoring (NIBP), pulse oximetry and capnography. Prior to the induction of general anesthesia patients baseline systolic BP, diastolic BP, and pulse rates will be recorded. Before induction of general anesthesia and prior to the skin incision, active noise cancelling headphones (Beyerdynamic DT 990 PRO) connected to a MP3 player (NW-E394 Walkman Digital music player) will be applied to all patients and removed before reversal of muscle relaxants (to ensure patient can comply with instructions from anesthetist).

Recovery - Reversal (neostigmine 0.04mg/kg & atropine 0.02mg/kg), extubation while under anesthesia & recovery (unless contraindicated).

No other music will be played in theaters during the surgery. According to the assigned group, a designated member of the research team (medical officer) chooses either a preselected religious chanting playlist or silence.

The patients assigned to the intervention group will be listening to recordings of religious chants from the onset of general anesthesia (GA) till wound closure. The religious chants include religious chants for each major religion in Sri Lanka (Buddhism, Hinduism, Islam, and Christianity). And then depending on the patient’s religion and preference the selected chant would be played.

For the patients in the control group the headphones will be applied as previously described however a blank file without audio will be played.

In both groups standard laparoscopic procedure previously described will be carried out. The umbilical port will be closed with 1/0 vicryl and the skin sutured with 4/0 subcutaneous Monocryl. All patients will have 2x2 inch plasters placed at port sites. The orogastric tube will be removed immediately and the patient will be transferred to recovery area immediately. Once the patients’ vital parameters are stable, the patient will be shifted to the general ward. Individualized management of each patient is at the discretion of the clinician & any deviation from protocol will be documented.

Post Operative baseline analgesia and drugs- Patients will be transferred to the recovery area and subsequently to the ward where their vitals (blood pressure, pulse rate) will be monitored at stipulated intervals as per the hospital protocol. All patients will receive morphine IV at OT Recovery and paracetamol 1g 6hourly & celecoxib 200mg bd and Ondansetron 8mg at 6 hours after surgery. S/C morphine 0.1mg/kg will be delivered based on patients’ demand. (Pain will be assessed every 6hourly using visual analogue score. If the pain score is more than 5 or if the patient is demanding S/C morphine 0.1mg/kg will be given).


Inclusion criteria

  1. All males and females >18 years old who undergo elective laparoscopic cholecystectomy for symptomatic gallstone disease or any other indication.

Exclusion criteria

  1. Patients who undergo emergency laparoscopic cholecystectomy.
  2. Those who are having conversion from laparoscopy to open cholecystectomy.
  3. Duration of surgery more than 3 hours.
  4. Patients who have undergone upper abdominal surgeries previously.
  5. Patients with known hearing impairment or usage of a hearing aid.
  6. Patients using systemic steroids, immunosuppressants or cytotoxic medications.
  7. Patients with chronic pain or on regular analgesics.


Primary outcome(s)

1.

Assessment of the intensity of post operative pain will be done using the Numeric Rating Scale (NRS) where where 0 = no pain, scores 1 to 3 = mild pain, 4 to 7 = moderate pain and 8 to 10 = severe pain.

[

Assessed 2,6,12,18,24 and 36 hours following surgery.

]

Secondary outcome(s)

1.

The requirements for the opioid analgesics (S/C morphine 0.1mg/kg) will be recorded as a total dose.

[

Assessed after 36 hours.

]
2.

Post operative Nausea and Vomiting will be assessed by the PONV 4 grade scale Post operative Nausea and Vomiting will be assessed by the PONV 4 grade scale: where 1 = no nausea, 2 = mild nausea, 3 = moderate nausea and 4 = severe nausea.

[

Assessed at 2,6,12,18,24, and 36 hours following surgery.

]
3.

Duration of immobilization: time taken to walk to the washroom after surgery

[

Assessed at 2,6,12,18,24, and 36 hours following surgery.

]
4.

Duration of hospital stay

[

At the time of discharge

]
5.

Overall wellbeing - assessed by GCS and general wellbeing

[

Assessed at 2,6,12,18,24, and 36 hours following surgery.

]
6.

Intra-operative vitals (blood pressure and pulse rate).

[

Recorded at every 30 min intervals by the anesthetic team along with the total opioid requirement will be retrieved using anesthetic charts after completion of the surgery.

]

Target number/sample size

70 (35 in each arm)


Countries of recruitment

Sri Lanka


Anticipated start date

2024-10-02


Anticipated end date

2025-02-02


Date of first enrollment

2024-10-01


Date of study completion


Recruitment status

Recruiting


Funding source

None


Regulatory approvals



State of Ethics Review Approval


Status

Approved


Date of Approval

2024-06-11


Approval number

P/71/06/2024


Details of Ethics Review Committee

Name: Ethics Revie Committee, Faculty of Medicine, University of Kelaniya
Institutional Address:Ethics Revie Committee, Faculty of Medicine, University of Kelaniya, PO box 06, Thalagolla road, Ragama, Sri Lanka
Telephone:0112961267
Email: ercmed@kln.ac.lk

Contact & Sponsor Information


Contact person for Scientific Queries/Principal Investigator

Prof. Rohan Chaminda Siriwardana
Consultant hepatobiliary surgeon
Colombo North Centre for Liver Diseases, Faculty of Medicine, University of Kelaniya, P.O Box 6, Thalagolla Road, Ragama, Sri Lanka
0775544015
0777250213

rohansiriwardana@yahoo.com

Contact Person for Public Queries

Prof. Rohan Chaminda Siriwardana
Consultant hepatobiliary surgeon
Colombo North Centre for Liver Diseases, Faculty of Medicine, University of Kelaniya, P.O Box 6, Thalagolla Road, Ragama, Sri Lanka
0775544015
0777250213

rohansiriwardana@yahoo.com


Primary study sponsor/organization

Colombo North Centre for Liver Diseases, Faculty of Medicine, University of Kelaniya.
Colombo North Centre for Liver Diseases, Faculty of Medicine, University of Kelaniya.
Colombo North Centre for Liver Diseases, Faculty of Medicine, University of Kelaniya, P.O Box 6, Thalagolla Road, Ragama, Sri Lanka
0112961000

cncldragama@gmail.com

Secondary study sponsor (If any)







Trial Completion details


Do the investigators plan to share identified individual clinical trial participant-level data (IPD)?

No


IPD sharing plan description

None


Study protocol available

Yes


Protocol version and date

Version 1, 20/05/2024



Results summary available

No


Date of posting results


Date of study completion


Final sample size


Date of first publication


Link to results


Brief summary of results